Quick Answer
No. There is no generic version of Jardiance available in the United States. The FDA has approved no generic empagliflozin for sale, and the patents currently listed with the agency run to at least February 2029. You do not have to wait that long to pay less, though. Brand-name Jardiance from a licensed Canadian pharmacy costs significantly less than typical US retail pricing and is available now with a valid prescription.
Jardiance generic name vs. a generic version of Jardiance
Empagliflozin is the generic name for Jardiance. That is not the same as a generic version of Jardiance, and confusing the two is why this question keeps getting asked in three different ways.
A generic name is simply the drug’s nonproprietary name, the chemical identity underneath the brand. Jardiance has had one since the FDA approved it in 2014. It implies nothing about competition or price.
A generic drug is a different product entirely: a copy made by a competing manufacturer, approved through an abbreviated application, and sold alongside the brand at a discount. That does not exist in the US market yet.
Why there is no generic for Jardiance yet
Patents, and a lot of them. The FDA’s Orange Book, the official register of patents listed against approved drugs, shows a drug substance patent on Jardiance running to August 1, 2028, extended to February 1, 2029 by a pediatric exclusivity award. Additional formulation and method-of-use patents sit behind it, several with expirations into the 2030s.
Generic manufacturers have not been idle. Several have filed applications challenging those patents, the route the FDA lays out in its guidance on Paragraph IV certifications and the 30-month stay. A number of those applications have already received tentative approval, which sounds closer to the finish line than it is. In the FDA’s own words, a tentative approval does not allow the applicant to market the generic drug product. The science cleared. The legal barrier did not move.
Those challenges have not broken through. Years after the first filings, the FDA still lists no approved generic empagliflozin available for sale, which is also why Jardiance qualified for Medicare price negotiation in the first place: that program covers only high-spend drugs with no generic or biosimilar competition.
Generic Empagliflozin (Jardiance): Where Things Stand
| Status as of September 2026 | |
|---|---|
| FDA-approved generic empagliflozin on the US market | None |
| Drug substance patent (Orange Book, application 204629) | Expires August 1, 2028 |
| Pediatric exclusivity extension | Runs to February 1, 2029 |
| Later formulation and method-of-use patents | Listed with expirations into the 2030s |
| Generic applications at the FDA | Multiple filed, several tentatively approved, none cleared to launch |
| Patent challenges by generic makers | Filed, but none has yet cleared a generic for launch |
Anyone quoting a firm launch date is guessing. February 2029 is the earliest the current listings support, and settlements, appeals, and newly listed patents can move it either way. Check the FDA listing rather than trusting a date you read last year.
What the wait actually costs you in 2026
That depends entirely on how you are covered, and the gap between groups is wide.
If you are on Medicare Part D, 2026 is the first year of Medicare’s negotiated drug prices, and Jardiance was one of the first ten drugs selected. CMS set the negotiated price at $197 for a 30-day supply, down from a 2023 list price of $573, a 66% reduction, effective January 1, 2026. Read the fine print, though. That is what Medicare and your plan pay. What you hand over at the counter is still set by your deductible and your plan’s cost sharing, alongside the new annual out-of-pocket cap.
If you have commercial insurance, your cost comes down to formulary tier and coinsurance. Manufacturer savings programs exist, but they are run by the manufacturer rather than by pharmacies, and federal law excludes anyone with Medicare, Medicaid, or other government coverage from using them.
If you are uninsured or in a high deductible plan, you are paying close to full price on a brand-only drug with no generic competition holding it down. Nearly 1.9 million Medicare Part D enrollees filled Jardiance prescriptions in 2023, according to CMS, which gives some sense of how many people are affected once you add every other coverage type. This is the group with the most to gain from a different source for the same medication.
You do not have to wait until 2029 to pay less
Brand-name Jardiance from a licensed Canadian pharmacy is available today, at significantly less than typical US retail pricing, with a valid prescription. A generic is one way to lower the price of a medicine. Buying the same brand-name medicine from a market where it costs less is another.
Jardiance is sold in Canada by the same manufacturer, in the same 10 mg and 25 mg tablets, under the same brand name. Canada regulates the price of patented medicines in a way the US does not, which is why an identical box costs a fraction of the US price. That gap has nothing to do with patents expiring and everything to do with where the pharmacy sits.
Buy Canadian Insulin fills brand-name Jardiance prescriptions through licensed pharmacy partners and ships to US addresses. Current pricing by strength and quantity is on the product page, including 30, 60, and 90 tablet options. A prescription from your own prescriber is required, the same as at any US pharmacy. Other oral diabetes medications are available on the same basis.
What arrives is not a substitute, an alternative, or a compounded version. It is Jardiance.
Before you switch drugs to save money
Do not switch on price alone. Jardiance is approved for more than blood sugar control, and the cheaper options are not equivalent trades.
Safety Note: Jardiance carries FDA approvals related to cardiovascular risk, heart failure, and chronic kidney disease, not just type 2 diabetes. A less expensive drug from a different class does not carry those approvals no matter how well it lowers A1c. Stopping or switching without your prescriber’s input can cost you protection you were prescribed the drug to get.
- Metformin is inexpensive and widely available as a generic, but it works by a completely different mechanism.
- Farxiga is the closest comparison, another SGLT2 inhibitor, but it is also brand-only in the US with patents on a similar timeline. Our Jardiance vs. Farxiga comparison covers the differences.
- If a prescriber has raised a GLP-1 medication with you, the Jardiance vs. Mounjaro comparison explains how the two work and who each is meant for.
On dosing, the FDA-approved prescribing information from Boehringer Ingelheim describes a usual starting dose of 10 mg once daily in the morning, which a prescriber may increase to 25 mg. Stretching a prescription by splitting tablets or skipping days is not a cost strategy. Bring the cost problem to your prescriber directly. They deal with it constantly and often have options you would not think to ask for.
Frequently Asked Questions
Articles you may also be interested in
